Drug-Device Combination Products: Supplying Trials Where the Drug Comes With a Device

More drugs now reach patients through a device: prefilled syringes, autoinjectors, pens, on-body injectors, inhalers. Patients prefer them, payers like home administration, and many biologics are only practical this way. For clinical supply, though, a combination product is two regulated things in one carton. The drug follows GMP for medicines. The device follows design controls and device quality rules. Your supply chain has to satisfy both, often across several vendors.

Know which version of the device you are using

Device development runs on its own timeline. A Phase 2 trial might use a vial and syringe, Phase 3 might use a prefilled syringe, and the commercial product might be an autoinjector. Each change can trigger bridging studies, new stability, and new packaging. Supply planning needs to know which device configuration each study uses, and when the switch happens.

If a trial transitions mid-study from one presentation to another, plan it like a protocol amendment. Sites need training, IRT needs new kit types, and old stock needs a clear end date.

The assembly chain is longer

A typical prefilled syringe in an autoinjector moves through several steps: fill-finish of the syringe, inspection, assembly into the device, labeling, and packaging. These steps may sit at different vendors, sometimes in different countries. Each handoff adds lead time, transport risk, and a quality release step.

• Map every step and vendor with lead times and capacity.
• Check device component supply. Autoinjector subassemblies and springs can have long lead times and minimum order quantities that dwarf trial needs.
• Plan assembly capacity early. Device assembly lines are often booked for commercial products, and clinical runs get squeezed.

Blinding a device

Blinding is harder when the device itself is visible. Placebo has to go into an identical device, with identical injection force, sound, and feel. If the active drug is viscous and the placebo is not, patients can tell the difference by how the plunger moves. Viscosity-matched placebo and careful device testing help. So does early agreement with the clinical team on what level of blinding is realistic.

Labeling and instructions for use

Combination products usually need instructions for use (IFU) in local languages, in addition to the clinical label. Device labels may need symbols and information required under medical device rules. Booklet labels get thick fast. Build label and IFU content into the label plan early, and confirm with regulatory which device requirements apply to investigational use in each country.

Storage, handling, and temperature

Many combination products are biologics that need 2 to 8 °C storage. Devices add bulk, so fewer units fit in each shipper and cold room. Some devices are sensitive to freezing or to shock, and a dropped autoinjector may fail even if the drug is fine. Include device-specific handling rules in site instructions and packaging qualification.

Complaints and device failures

A failed injection is both a device complaint and a potential dosing deviation. Set up a clear process for sites to report device malfunctions, return the device for investigation, and replace the dose quickly. Track complaints by lot. A cluster of failures from one assembly lot is a quality signal you want to catch early.

Home administration and direct-to-patient

Self-injection devices make home dosing possible, which pairs naturally with direct-to-patient supply. That adds patient training, home storage guidance, sharps disposal, and return of used devices for accountability. Decide early whether patients return used devices, and if so how, because sharps transport has its own rules.